Disclosed is a pharmaceutical composition comprising R (+) budesonide and one or more beta2-agonists selected from albuterol, levoalbuterol, terbutaline, pirbuterol, procaterol, metaproterenol, fenoterol, bitolterol mesylate, ritodrine, salmeterol, carmoterol, bambuterol, clenbuterol, indacaterol, milveterol, vilanterol, or olodaterol, and, optionally, one or more pharmaceutically acceptable excipients. The disclosed compositions may be used for relief from bronchial disorders, while simultaneously reducing undesirable side effects commonly experienced by corticosteroid users.
